Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 14/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PAICS | P22234 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31408545 | 0.89 | PTGES (0.46) | SMN1; SMN2PTGESACACBPRKAG1PRKAA1 | |
| SCHEMBL31408354 | 0.88 | PRKAG1 (0.48) | SMN1; SMN2PTGESPRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31408441 | 0.85 | PTGES (0.49) | SMN1; SMN2PTGES | |
| SCHEMBL31408311 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2PTGESPRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31408456 | 0.85 | PTGES (0.47) | SMN1; SMN2PTGESPRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31408629 | 0.82 | PTGES (0.42) | SMN1; SMN2PTGES | |
| SCHEMBL31408611 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31408586 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31408238 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31408351 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049604-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |